Now showing items 1-20 of 108

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03)
      Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
    • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. 

      Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)
      Background The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ...
    • A case-control study of risk of leukaemia in relation to mobile phone use. 

      Cooke, R; Laing, S; Swerdlow, AJ (2010-11)
      Background Mobile phone use is now ubiquitous, and scientific reviews have recommended research into its relation to leukaemia risk, but no large studies have been conducted.Methods In a case-control study in South East ...
    • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. 

      Coignard, J; Lush, M; Beesley, J; O'Mara, TA; Dennis, J; Tyrer, JP; Barnes, DR; McGuffog, L; Leslie, G; Bolla, MK; Adank, MA; Agata, S; Ahearn, T; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Arnold, N; Aronson, KJ; Arun, BK; Augustinsson, A; Azzollini, J; Barrowdale, D; Baynes, C; Becher, H; Bermisheva, M; Bernstein, L; Białkowska, K; Blomqvist, C; Bojesen, SE; Bonanni, B; Borg, A; Brauch, H; Brenner, H; Burwinkel, B; Buys, SS; Caldés, T; Caligo, MA; Campa, D; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Conroy, DM; Czene, K; Daly, MB; Devilee, P; Diez, O; Ding, YC; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Dwek, M; Eccles, DM; Eliassen, AH; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Flyger, H; Fostira, F; Friedman, E; Fritschi, L; Frost, D; Gago-Dominguez, M; Gapstur, SM; Garber, J; Garcia-Barberan, V; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Gayther, SA; Gehrig, A; Georgoulias, V; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; He, W; Hogervorst, FBL; Hollestelle, A; Hopper, JL; Horcasitas, DJ; Hulick, PJ; Hunter, DJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Jager, A; Jakubowska, A; James, PA; Jensen, UB; John, EM; Jones, ME; Kaaks, R; Kapoor, PM; Karlan, BY; Keeman, R; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Kosma, V-M; Kraft, P; Kurian, AW; Laitman, Y; Lambrechts, D; Le Marchand, L; Lester, J; Lesueur, F; Lindstrom, T; Lopez-Fernández, A; Loud, JT; Luccarini, C; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mebirouk, N; Meindl, A; Miller, A; Milne, RL; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; O'Brien, KM; Olopade, OI; Olson, JE; Olsson, H; Osorio, A; Ottini, L; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peshkin, B; Peterlongo, P; Peto, J; Pharoah, PDP; Phillips, K-A; Polley, EC; Poppe, B; Presneau, N; Pujana, MA; Punie, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Rennert, HS; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sandler, DP; Santella, R; Scheuner, MT; Schmidt, MK; Schmidt, G; Scott, C; Sharma, P; Soucy, P; Southey, MC; Spinelli, JJ; Steinsnyder, Z; Stone, J; Stoppa-Lyonnet, D; Swerdlow, A; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Teulé, A; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Trainer, AH; Truong, T; Tung, N; Vachon, CM; Vega, A; Vijai, J; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wolk, A; Yadav, S; Yang, XR; Yannoukakos, D; Zheng, W; Ziogas, A; Zorn, KK; Park, SK; Thomassen, M; Offit, K; Schmutzler, RK; Couch, FJ; Simard, J; Chenevix-Trench, G; Easton, DF; Andrieu, N; Antoniou, AC (2021-02-17)
      Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in ...
    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. 

      Eccleston, A; Bentley, A; Dyer, M; Strydom, A; Vereecken, W; George, A; Rahman, N (2017-04)
      Objectives To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and second-degree ...
    • A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). 

      Turner, NC; Telli, ML; Rugo, HS; Mailliez, A; Ettl, J; Grischke, E-M; Mina, LA; Balmaña, J; Fasching, PA; Hurvitz, SA; Wardley, AM; Chappey, C; Hannah, AL; Robson, ME; ABRAZO Study Group (2019-05)
      PURPOSE:To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer. PATIENTS AND METHODS:ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) in ...
    • Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. 

      Schmidt, MK; Hogervorst, F; van Hien, R; Cornelissen, S; Broeks, A; Adank, MA; Meijers, H; Waisfisz, Q; Hollestelle, A; Schutte, M; van den Ouweland, A; Hooning, M; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Arndt, V; Bermisheva, M; Bogdanova, NV; Bolla, MK; Brauch, H; Brenner, H; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dunning, AM; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Haeberle, L; Hall, P; Hillemanns, P; Hopper, JL; Jakubowska, A; John, EM; Jones, M; Khusnutdinova, E; Knight, JA; Kosma, V-M; Kristensen, V; Lee, A; Lindblom, A; Lubinski, J; Mannermaa, A; Margolin, S; Meindl, A; Milne, RL; Muranen, TA; Newcomb, PA; Offit, K; Park-Simon, T-W; Peto, J; Pharoah, PDP; Robson, M; Rudolph, A; Sawyer, EJ; Schmutzler, RK; Seynaeve, C; Soens, J; Southey, MC; Spurdle, AB; Surowy, H; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Trentham-Dietz, A; Vachon, C; Wang, Q; Whittemore, AS; Ziogas, A; van der Kolk, L; Nevanlinna, H; Dörk, T; Bojesen, S; Easton, DF (2016-08)
      Purpose CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its ...
    • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. 

      Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; Neven, P; Park, YH; Prat, A; Bachelot, T; Juric, D; Turner, N; Sophos, N; Zarate, JP; Arce, C; Shen, Y-M; Turner, S; Kanakamedala, H; Hsu, W-C; Chia, S
      Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in ...
    • An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. 

      Maley, CC; Koelble, K; Natrajan, R; Aktipis, A; Yuan, Y (2015-09-22)
      Introduction Abundance of immune cells has been shown to have prognostic and predictive significance in many tumor types. Beyond abundance, the spatial organization of immune cells in relation to cancer cells may also have ...
    • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. 

      Wyszynski, A; Hong, C-C; Lam, K; Michailidou, K; Lytle, C; Yao, S; Zhang, Y; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; González-Neira, A; Benitez, J; Neuhausen, SL; Brenner, H; Dieffenbach, AK; Meindl, A; Schmutzler, RK; Brauch, H; GENICA Network; Nevanlinna, H; Khan, S; Matsuo, K; Ito, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; kConFab Investigators; Australian Ovarian Cancer Study Group; Wu, AH; Van Den Berg, D; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Couch, FJ; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Dumont, M; Teo, SH; Wong, TY; Kristensen, V; Zheng, W; Long, J; Winqvist, R; Pylkäs, K; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Figueroa, J; Klevebring, D; Czene, K; Hooning, MJ; van den Ouweland, AMW; Darabi, H; Shu, X-O; Gao, Y-T; Cox, A; Blot, W; Signorello, LB; Shah, M; Kang, D; Choi, J-Y; Hartman, M; Miao, H; Hamann, U; Jakubowska, A; Lubinski, J; Sangrajrang, S; McKay, J; Toland, AE; Yannoukakos, D; Shen, C-Y; Wu, P-E; Swerdlow, A; Orr, N; Simard, J; Pharoah, PDP; Dunning, AM; Chenevix-Trench, G; Hall, P; Bandera, E; Amos, C; Ambrosone, C; Easton, DF; Cole, MD (2016-09)
      Breast cancer is the most diagnosed malignancy and the second leading cause of cancer mortality in females. Previous association studies have identified variants on 2q35 associated with the risk of breast cancer. To identify ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      Importance The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. 

      Rambau, PF; Vierkant, RA; Intermaggio, MP; Kelemen, LE; Goodman, MT; Herpel, E; Pharoah, PD; Kommoss, S; Jimenez-Linan, M; Karlan, BY; Gentry-Maharaj, A; Menon, U; Polo, SH; Candido Dos Reis, FJ; Doherty, JA; Gayther, SA; Sharma, R; Larson, MC; Harnett, PR; Hatfield, E; de Andrade, JM; Nelson, GS; Steed, H; Schildkraut, JM; Carney, ME; Høgdall, E; Whittemore, AS; Widschwendter, M; Kennedy, CJ; Wang, F; Wang, Q; Wang, C; Armasu, SM; Daley, F; Coulson, P; Jones, ME; Anglesio, MS; Chow, C; de Fazio, A; García-Closas, M; Brucker, SY; Cybulski, C; Harris, HR; Hartkopf, AD; Huzarski, T; Jensen, A; Lubiński, J; Oszurek, O; Benitez, J; Mina, F; Staebler, A; Taran, FA; Pasternak, J; Talhouk, A; Rossing, MA; Hendley, J; AOCS Group; Edwards, RP; Fereday, S; Modugno, F; Ness, RB; Sieh, W; El-Bahrawy, MA; Winham, SJ; Lester, J; Kjaer, SK; Gronwald, J; Sinn, P; Fasching, PA; Chang-Claude, J; Moysich, KB; Bowtell, DD; Hernandez, BY; Luk, H; Behrens, S; Shah, M; Jung, A; Ghatage, P; Alsop, J; Alsop, K; García-Donas, J; Thompson, PJ; Swerdlow, AJ; Karpinskyj, C; Cazorla-Jiménez, A; García, MJ; Deen, S; Wilkens, LR; Palacios, J; Berchuck, A; Koziak, JM; Brenton, JD; Cook, LS; Goode, EL; Huntsman, DG; Ramus, SJ; Köbel, M (2018-10)
      We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade ...
    • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. 

      Filipits, M; Dafni, U; Gnant, M; Polydoropoulou, V; Hills, M; Kiermaier, A; de Azambuja, E; Larsimont, D; Rojo, F; Viale, G; Toi, M; Harbeck, N; Prichard, KI; Gelber, RD; Dinh, P; Zardavas, D; Leyland-Jones, B; Piccart-Gebhart, MJ; Dowsett, M; TransHERA investigators (2018-07)
      Purpose: To assess the prognostic and predictive value of selected biomarkers involved in cell-cycle regulation or proliferation in patients with HER2-positive early breast cancer.Experimental Design: Protein expression ...
    • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. 

      Shu, X; Wu, L; Khankari, NK; Shu, X-O; Wang, TJ; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Milne, RL; Schmidt, MK; Pharoah, PDP; Andrulis, IL; Hunter, DJ; Simard, J; Easton, DF; Zheng, W; Breast Cancer Association Consortium (2019-06)
      Background In addition to the established association between general obesity and breast cancer risk, central obesity and circulating fasting insulin and glucose have been linked to the development of this common malignancy. ...
    • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. 

      Sonnenblick, A; Bailey, A; Uziely, B; Untch, M; Smith, I; Gianni, L; Baselga, J; Jackisch, C; Cameron, D; Bell, R; Zardavas, D; Al-Sakaff, N; Gelber, RD; Dowsett, M; Leyland-Jones, B; Piccart-Gebhart, MJ; DE Azambuja, E (2019-02)
      BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based ...
    • Brain and Salivary Gland Tumors and Mobile Phone Use: Evaluating the Evidence from Various Epidemiological Study Designs. 

      Röösli, M; Lagorio, S; Schoemaker, MJ; Schüz, J; Feychting, M (2019-04)
      Mobile phones (MPs) are the most relevant source of radiofrequency electromagnetic field (RF-EMF) exposure to the brain and the salivary gland. Whether this exposure implies a cancer risk has been addressed in several ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. 

      Cooke, R; Jones, ME; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Illidge, T; Linch, DC; Lister, TA; Lucraft, HH; Radford, JA; Stevens, AM; Syndikus, I; Williams, MV; England and Wales Hodgkin Lymphoma Follow-up Group; Swerdlow, AJ (2013-06)
      Background Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-08)
      Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and ...
    • Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. 

      Clendenen, TV; Ge, W; Koenig, KL; Afanasyeva, Y; Agnoli, C; Brinton, LA; Darvishian, F; Dorgan, JF; Eliassen, AH; Falk, RT; Hallmans, G; Hankinson, SE; Hoffman-Bolton, J; Key, TJ; Krogh, V; Nichols, HB; Sandler, DP; Schoemaker, MJ; Sluss, PM; Sund, M; Swerdlow, AJ; Visvanathan, K; Zeleniuch-Jacquotte, A; Liu, M (2019-03-19)
      BACKGROUND:Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a ...